On January 14, 2014, Aeterna Zentaris, a specialty biopharmaceutical company engaged in developing novel treatments in oncology and endocrinology, completed an equity issuance by way of public offering under a prospectus supplement in the United States of units comprised of common shares and common share purchase warrants for gross proceeds of US$13.2 million.
Aeterna Zentaris intends to use the net proceeds from the offering to continue to fund its ongoing drug development activities, primarily for the advancement of its zoptarelin doxorubicin (AEZS-108) program, secondly for its macimorelin acetate (AEZS-130) program, including the preparation of its commercial launch, as well as for the potential addition of commercialized products to the Company’s pipeline, future negative cash flow, general corporate purposes and working capital. Canaccord Genuity Inc. acted as the sole book-running manager, and Maxim Group LLC, H. C. Wainwright & Co., LLC and MLV & Co LLC acted as co-managers for the offering.
Norton Rose Fulbright Canada LLP acted as lead counsel to Aeterna Zentaris. Norton Rose Fulbright’s team was led by Elliot Shapiro and included Meghan Stewart, Catherine Simard and Andrei Molchynsky (Corporate and Securities) and Derek Chiasson and Antoine Desroches (Tax).